BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Pharm Country

  Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), today announced positive topline results from Part 2 of the EPIPHAST study for its AQST-109 epinephrine oral film.

  April 12, 2022

   · 

  12 min read
• Drug Development

  AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis

  AbbVie (NYSE: ABBV) today announced new data from a Phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis.

  April 12, 2022

   · 

  8 min read
• Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment

  Renexxion Ireland Ltd. announced that it has entered into a share subscription agreement with GEM Global Yield LLC SCS, a Luxembourg-based private equity group for an investment of up to $100 Million to be made within 36 months after a public listing.

  April 12, 2022

   · 

  2 min read
• Business

  Oak Hill Bio Announces Formation of Board of Directors

  Oak Hill Bio today announced the formation of the Company’s Board of Directors, which brings together a team of experienced leaders with collective expertise spanning financing, business operations, drug discovery, clinical development and biopharmaceutical business development.

  April 12, 2022

   · 

  5 min read
• Drug Development

  OncoNano Medicine Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD™ Platform at AACR 2022 Annual Meeting

  OncoNano Medicine, Inc. today announced positive results from the company’s ON-BOARD™ pH-sensitive nanoparticle platform.

  April 12, 2022

   · 

  2 min read
• Business

  Secarna Pharmaceuticals’ Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb

  Secarna Pharmaceuticals GmbH & Co. KG has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a payment of US$ 16 m to Evotec.

  April 12, 2022

   · 

  6 min read
• Drug Development

  Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

  Ocugen, Inc. announced that the Company was informed by the U.S. Food and Drug Administration (FDA) that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN™ (BBV152), OCU-002, on clinical hold.

  April 12, 2022

   · 

  2 min read
• Biotech Bay

  Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences

  Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that management plans to participate in seven upcoming investor conferences.

  April 12, 2022

   · 

  2 min read
• Business

  SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

  Sera Prognostics Inc. today announced that Dr. Jane F. Barlow has joined the Sera Board of Directors.

  April 12, 2022

   · 

  6 min read
• Deals

  Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  Kintara Therapeutics, Inc. today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 16,226,416 shares of the Company’s common stock.

  April 12, 2022

   · 

  5 min read